Syneron Medical Ltd announced the FDA and Health Canada clearance and commercial launch of its CO2RE CO2 resurfacing system.

CO2RE is a versatile fractional CO2 system that offers the unique ability to treat both superficial and deep skin layers simultaneously with precision-control over the intensity, pattern, and depth of ablation. This patent-pending technology is the first to receive FDA clearance for all of its operating modes, including the four major fractional treatment modes. The system can be used for fractional CO2 resurfacing and traditional ablation, and is ideal for skin rejuvenation, wrinkle reduction, scar reduction and other aesthetic procedures.

"We received very positive physician feedback during the international roll-out of the CO2RE system and we are excited to begin offering it in the United States and Canada, giving our customers more choices and greater flexibility to meet their individual practice needs. With the addition of CO2RE, we now offer a complete range of product solutions that address physicians’ and patients’ needs across a wide range of facial rejuvenation treatment categories," sas Louis P. Scafuri, CEO of Syneron. "The launch of CO2RE shows the strength of our globalized approach to research and development. The product was developed by Inlight Inc., San-Diego, Calif, which was acquired by Syneron at the end of 2008. Inlight brought to Syneron the most advanced scanner and ablative laser technology which, in combination with Syneron’s know-how in light tissue interaction, enabled us to bring to the market the most advanced and versatile system for a wide range of ablative skin rejuvenation procedures."

"We’ve been very happy with the results that we’ve seen using CO2RE. It has a lot of versatility and we find it works well for both fractionated ablative resurfacing as well as traditional ablative resurfacing," says Brian Zelickson, MD, a board-certified dermatologist at the Zel Skin and Laser Specialists, in Edina, Minn.


[Source: Syneron Medical Ltd/Medical News Today]